Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Uroplasty/Empi

This article was originally published in The Gray Sheet

Executive Summary

Letter of intent is signed under which urinary incontinence treatment firm Uroplasty will purchase Empi's Clinical EMG System for $400,000. The product is a biofeedback device used to treat UI. Closing of the deal is subject to certain conditions, including the negotiation and execution of a definitive agreement and Uroplasty's due diligence review of "certain software" related to the system, according to Minneapolis-based Uroplasty, which is developing the Macroplastique injectable treatment for female stress UI
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT012249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel